Breast Cancer Trial, Recruiting NCT07066917 Sponsor: Hellenic Cooperative Oncology Group Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT07066917
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older.
  • People with advanced breast cancer that has been confirmed through laboratory testing of tissue samples.
  • People whose breast cancer falls into one of these categories: hormone receptor positive, HER2-positive or HER2-low, or triple negative breast cancer (TNBC) (confirm with trial site if unsure which category applies).
  • Participation in the analysis requires that at least one full treatment cycle has already been completed.

Who may not be able to join:

  • People diagnosed with early-stage breast cancer at the time of enrolling in the trial.
  • People who are unwilling to sign a consent form agreeing to take part in the trial.
  • People who are unwilling to provide a biological sample (such as blood or tissue) as part of the trial.
  • People for whom complete and detailed medical records are not available.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Elena Fountzilas, MD, PhD, Hellenic Cooperative Oncology Group

Phone: +302106912520

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hellenic Cooperative Oncology Group
Registry
ClinicalTrials.gov
Start date
15 October 2024
Est. completion
1 October 2029

Where this trial is recruiting

🇬🇷 Greece

Primary endpoints

Progression-free survival (PFS); Overall Survival (OS); Objective Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov